Selected types of severe combined immunodeficiencies (SCID) [acc. 1]
The list of primary immunodeficiencies (PID) includes now more than 200 different diseases and syndromes characterised by dysfunction of immune system with different epidemiology ranging from common, like selected IgA deficiency, to very rare, diagnosed in singular patients. The deficiencies of humoral immunity are frequent including transient hypogammaglobulinemia of infants (THI), common variable immunodeficiency (CVID), selected IgA deficiency (IgAD), hyper IgM syndrome (hyperIgM) or agammaglobulinemia (XLA). The hypogammaglobulinemia of selected immunoglobulins’ class (IgG or IgA) or all classes (e.g. CVID) are associated with allergy and autoimmunity in significant percentage of patients. The hypothesis explaining autoimmune diseases in humoral immunodeficiency includes presence of autoreactive T and B lymphocytes, deregulation of immune response associated with number and function of T regulatory cells and other mechanisms. The typical clinical symptoms of autoimmune process in patients with humoral deficiency (CVID, IgAD, hyper IgM) include cytopenias, gastrointestinal tract diseases like celiac or inflammatory bowel diseases, endocrine system autoimmunity, rheumatoid arthritis and systemic autoimmune diseases. The diagnosis of autoimmunity in humoral immunodeficiency is difficult, due to low production of antibodies, overlapping of clinical symptoms of immunodeficiency and autoimmunity. Autoimmunity is noted also in group of well defined immunodeficiency or immunodysregulation syndromes with autoimmune symptoms as criteria of given immunodeficiency, e.g., autoimmune lymphoproliferative syndrome (ALSP) and Wiskott-Aldrich syndrome (WAS). Therapy of autoimmunity in immunodeficient patients includes steroids, immunosuppression, similar to patients without PID. However, if, in some patients with PID, the standard therapy of autoimmune disease is not effective, the immunoglobulins in high dose and/or, monoclonal antibodies are used. Progress and severity of autoimmune process, resistance to therapy, life-threatening symptoms are now the indications for haematopoietic stem cells transplantation for these patients.
2. Introduction to primary immunodeficiency associated with autoimmunity
The primary immunodeficiencies (PID) consist of more than 200 diseases with one common background – dysfunction of immune system as effect of T, B lymphocytes, NK cells and neutrophils’ disturbances in ontogeny and function. The first, most extreme group of PIDs are severe combined immunodeficiencies (SCID) characterised by the lack of immunocompetent cell populations. In these deficiencies, the different patterns of lack of cells are noted- without T lymphocytes and/or NK cells (SCID T-B+NK-, SCID T-B+NK+), and/or B lymphocytes (SCID T-B-NK-, SCID T-B-NK+). The one way to safe life of newborn babies and infants with SCID is haematopoietic stem cells transplantation (HSCT) from matched related or unrelated donor (Table 1). In SCID, the autoimmunity is rare, practically seen only in Omenn’s syndrome (Rag1/Rag2 deficiency). In this type of SCID, besides antibacterial, antifungal, antiviral therapy, substitution of immunoglobulins as standard therapy for SCID, the use of steroids and/or cyclosporine A is indicated to resolve the erythrodermia and eosinophilia. This symptomatic therapy is effective in majority of patients. Thrombocytopenia, neutropenia and leukopenia are often due to hyperactivity of spleen.
Gamma chain deficiency
|T, NK decreased, B normal, low IgG||Defect of receptors for: IL-2, -4, -7, -9, -15, -21,
|Severe infections (bacterial, viral, fungal), failure to thrive||Antibiotics, antimycotics, IVIG substitution, HSCT as curative|
|Other deficiency with known genetic background||like above||JAK3, IL-7R alfa chain, CD45 deficiency
|Like above||Like above|
|T, B, NK decreased, IgG low, IgE high||RAG1/RAG2||Erythrodermia, eosinophilia, autoimmunity, CMV infection, splenomegaly||Steroids and/or cyclosporine A, IVIG, antibacterial, antiviral therapy, HSCT|
|Reticular dysgenesis||T, B, NK decreased, low IgG||Adenylate kinase (AK2) deficiency||Neutropenia, deafness||Antibiotics, antimycotics,
Antiviral therapy, IVIG, HSCT
|Adenosine deaminase deficiency (ADA)||may be progressive decrease of T, B, NK cells number||ADA deficiency||Costochondral junction flaring, neurological features, hearing impairment, lung and liver involvement||Like above|
|MHC class I||decreased CD8, normal B and NK cells||TAP, TAP2 or TAPBP mutation||Severe infections, vasculitis||Like above|
|MHC class II||decreased CD4, normal B and NK cells number||Transcription factors mutation (CIITA, RFX5, RFXAP, RFXANK)||Infections, failure to thrive, chronic diarrhoea||Like above|
In general consensus, the primary immunodeficiencies are divided into groups depending on the basic defect: humoral immunodeficiency –- common deficiency with prevalence of disorders in immunoglobulins and antibodies production, cellular immunodeficiency and well-defined syndromes of immunodeficiency with prevalence of cellular mechanisms leading to functional deficiency. The bacterial, viral infections with severe clinical course and poor response to therapy are common and typical symptoms of immune deficiency, due to lack of proper reaction of immune system. In patients with SCID, these infections are life-threatening and together with failure to thrive and weight gaining, they lead to death within first year of life. The autoimmunity process and symptoms are noted as associated disease or complications in different types of immune deficiency. The autoimmunity, in particular types of PID (e.g. hyper IgM syndrome, autoimmune lymphoproliferative syndrome (ALPS), Wiskott-Aldrich syndrome (WAS), is one of criteria of these immunodeficiencies (Table 2). In CVID, one of common immune deficiency of immunoglobulin and specific antibodies synthesis, the autoimmune co-existent process and diseases are noted in more than 30% of patients (up to 60% in different groups). The similar frequency of autoimmunity is observed within IgA deficiency patients.
|Decreasing T number, B normal, IgA, IgE increased||Mutation in WAS
|Microthrombocytopenia, eczema, autoimmunity, IgA nephropathy, infections, lymphoma||Antibiotics, antiviral therapy, IVIG, HSCT|
1.Fas defect (CD95)
4. Caspase 8
(CD3/CD4-/CD8-), normal B
and NK cells
|Mutation of TNFRSF6 (surface apoptosis receptor)
Mutation TNFSF6 (Fas ligand)
Mutation of Casp10 (intracellular apoptosis pathway)
Mutation of Casp8
|Lymphadenopathy, splenomegaly, cytopenias, high or normal IgG level
Lymphadenopathy, splenomegaly, cytopenias, recurrent bacterial and viral infections, low IgG
|Steroids (often resistance), high-dose IgG, MMF, sirolimus, HSCT|
crinopathy, candidiasis, enctodermal dystrophy
|T, B and NK cells normal, IgG normal||Mutation of AIRE||Autoimmunity of endocrinal glands, chronic candidiasis, hypoplasia of dental enamel||Symptomatic supplementary therapy, steroids|
|IPEX polyendocrino pathy, enteropathy||Impaired function of T regulatory, B and NK cells normal, high IgA, IgE||Mutation of FOXP3
|Autoimmune enteropathy, diabetes, thyroiditis, eczema, haemolytic anaemia, thrombocytopenia||Symptomatic therapy|
|CD25 deficiency||T, B and NK cells normal||Mutation of IL-2 receptor alfa chain||Lymphoproliferation, autoimmunity||Symptomatic therapy|
The primary immunodeficiency described below are selected from a list of known PIDs, based on high frequency or obligatory occurrence of autoimmunity, before or during the course of basic immunodeficiency disease [1-11].
2.1. Humoral immunodeficiency
The pathogenesis of IgAD is based on the defective terminal maturation of B cells into IgA secreting plasma cells, resulting in reduced levels of serum and secretory (mucosal) IgA (sIgA) [5, 22]. The IgA circulating in serum consists of IgA1 and IgA2 subclasses. Depending on the localisation of IgA production’, the monomeric and dimeric forms of IgA (with joining (J)-chain in structure) are noted – monomeric circulating in serum, dimeric seen on surface of mucous membranes of small and large intestine, respiratory and urinary tract. The sIgA is produced by cells present within lymphoid tissue under the mucous membranes (MALT) [22, 24]. sIgA composed of IgA2 molecules characterise high resistance to enzymatic digestion by bacterial proteases. This secretory IgA immunoglobulin plays an important role in protection of mucous membranes from pathogens present within the lumen by agglutinating activity and facilitating the clearance of pathogens in the gastrointestinal, respiratory and urinary tracts . Functions of sIgA include direct neutralization of pathogens, intracellular neutralization of viruses during transepithelial transport and inhibition of receptors-mediated activation of immune system. The role of sIgA in selection of antigens entering through the mucous membrane is also postulated. The lack of sIgA on surface of mucous membranes is compensated by IgG and IgM [22, 25].
The observations of CVID in children showed heterogeneity of clinical symptoms like in adults, but the course of disease is often different. In a large study of 248 CVID patients (children and adults), majority of them (90%) showed severe and recurrent infections, mostly in the respiratory tract . Chronic lung disease developed in a reasonable number (27%) of adult patients. Recurrent infections of lower respiratory tract may lead to the development of bronchiectases. However, the bronchiectases may also be the result of few but severe and prolonged lung infections. In young children, chronic lung disease and bronchiectases are rare. Observations in a group of teenagers suggest that the time of CVID onset and duration are important for the occurrence of these complications. Moreover, in children with CVID, lymphoid interstitial pneumonia (LIP), an unusual and rare type of lung disease, is observed . In our group of 52 children with CVID, the histology of lung biopsy showed LIP in 3 patients (2 boys and a girl). Chronic sinusitis, LIP or bronchiectases develop and progress independently of regular substitution of IgG, even in higher doses [38, 39].
2.2. Cellular immunodeficiency with autoimmunity
|Family history of ALPS Age of diagnosis Lymphadenopathy Splenomegaly||No 20 months
|Father – mild form
12 days of life
High dose IVIG
Other – sirolimus
Course of transplant
Loss of chimerism
Loss of chimerism
Platelets (/ul) before and
Leukocytes (/ul) before
Hemoglobin (g/l) before
3. Pathogenesis of autoimmunity in humoral immunodeficiency
3.1. Role of autoantibodies
Autoantibodies are produced in the same way, like antibodies to pathogens and vaccine antigens, by B-1 subpopulation of B lymphocytes and plasma cells. The main production is localised in lymph nodes and bone marrow. Autoantigens originate from cells and tissues, so the structure of cell surface (e.g. determinants, receptors present on cell), products of cell (enzymes, hormones, pro-hormones, cytokines and other) and particles released after cell death have become recognised antigens. Autoantibodies against DNA result from circulation of nucleosomes containing DNA. The persistence of small population of self-reacting T and B lymphocytes in thymus and bone marrow in physiology is responsible for physiological presence of autoantibodies at low level. The increased occurrence and increasing amount of autoantibodies with age, suggest the presence of this small population of self-reactive lymphocytes during the entire lives of healthy people .
The inducing factor of autoantibodies production is not known to date, so different views are postulated, e.g. chronic inflammation, molecular mimicry with microbial antigens, aberrant expression of HLA-DR on cell surface (facilitating factor for immune response) as triggering signal. However, in diseases like lupus with intracellular autoantigen, this hypothesis is not very suitable. Perhaps the release of cytoplasmic organelles by dying cells and formation of nucleosomes containing pure DNA, induce production of antibodies against them. The antibodies’ pattern (e.g. against histones, centromers, centriols, nucleoli, Golgi apparatus, mitochondria, peroxidase, specific proteins: Scl-70, RNP) is typical for particular diseases, but the association between autoantibodies’ pattern and clinical features is far from explained . The high level of autoantibodies present in serum is, in general view, associated with damage of target cells, tissues or organs, followed by occurrence of clinical symptoms. The reaction of antibodies with antigen forms immune complexes which circulate in serum and/or produce deposits in capillary vessels, in the tissue expressing the autoantigen. With time, injury of tissue is enough for clinical onset of disease. These immune complexes bind the complement and activate its cascade, stimulating the production of pro-inflammatory cytokines, chemotactic factors for infiltrating cells. This stimulation and hyper activation of immunocompetent cells support the permanent synthesis of autoantibodies and amplification of chronic inflammation (self-perpetuating inflammatory process). The antibodies play important role in the pathomechanism of clinical symptoms in autoimmune diseases, though, not in all of them. Although, the precise role of autoantibodies is unknown, their persistent production suggests the participation in pathomechanism of disease. For example, the anti-transglutaminase antibodies present in celiac disease are associated with reduction of intestinal epithelial cells endocytosis, differentiation and proliferation, which results in decreased function of intestinal/epithelial barrier. In histology of mucous membrane in untreated celiac disease, the epithelium tends to blister or totally detach from the basement membrane, possibly the effect of inhibition of epithelial cells adhesion caused by antibodies . On the other hand, the role of autoantibodies in pathomechanisms of tissue damage in inflammatory bowel diseases (IBD – Leśniowski-Crohn’s disease and ulcerative colitis) is not fully described [51-53].
3.2. Production of autoantibodies in immunodeficiency
The serological diagnosis of autoimmune diseases is based on autoantibodies circulating in the serum, as a marker of this process and presence of tissue deposits containing autoantibodies and complement. In CVID, the production of specific antibodies including autoantibodies is low, due to immune system dysfunction. Moreover, in CVID the deficiency of IgA is frequent, so there is lack of antibodies in this immunoglobulin class. The histology of affected tissues, in patients without PIDs, is typical and well known. In this group of patients, as an effect of immunoglobulins and cells deficiency, the histology of affected tissue by autoimmune process is different. B-cell deficiency and disturbances in maturation (e.g. memory cell decrease, low number of plasma cells) are probable causes of different histology of intestine in IBD present in CVID patients [8, 54]. In biopsy of jejunum mucous in celiac or Leśniowski-Crohn’s disease in CVID patients, the infiltrates contain T lymphocytes, almost exclusively, with low number of B and plasma cells. To differentiate atypical histological pattern of intestine infiltrates in CVID from typical histology of affected intestine in otherwise healthy patients, the celiac disease and Leśniowski-Crohn’s disease are termed “celiac-like, ” and “Crohn-like” for CVID patients [8, 55-57].
In IgAD patients with celiac disease, the production of antibodies to gliadin, endomysium and tissue transglutaminase are preserved, but in IgG class. However, in some IgAD patients, the presence and high level of anti-transglutaminase antibodies may be shown in IgA, despite lack of IgA in serum (assayed with nephelometry). In these cases, the trace level of IgA in serum is enough to show antibodies to tissue transglutaminase, but with high sensitivity technique (e.g. ELISA). The histology of jejunum in IgAD patients is typical for celiac disease and similar to observed in children without IgAD. In some IgAD patients, serological diagnosis of celiac disease is suggested by other symptoms then directly associated with digestive tract (e.g. underweight, inhibition of growth, afts, low iron level). Moreover, in these patients, the typical changes of structure of jejunum villi may be absent (Marsh type 0). The time of introduction of restricted gluten-free diet (GFD) is a matter of discussion, depending on clinical symptoms from digestive tract, occurrence or progress of other symptoms, e.g. growth inhibition, loss of weight. It is obvious that in IgAD, plasma cells producing IgA are missing, although, total number of plasma cells is normal within infiltrates in jejunum. The GFD is effective in resolving the clinical symptoms of celiac disease in majority of IgAD patients [25, 55].
In CVID, the serological diagnosis of celiac disease is more difficult and doubtful, due to low production of antibodies both in IgG and IgA due to IgA deficiency in CVID [7-8, 55]. However, the permanent stimulation with autoantigens and antigens (e.g. gliadin) is enough to induce and to support the synthesis of antibodies/autoantibodies, overcoming the impaired function of immune system. The level of autoantibodies in serum is often lower than in patients without immune deficiency [54, 56-58]. In our observations, these antibodies present in low level were clinically significant, so, they should be considered in CVID patients as marker of celiac disease.
3.3. Role of T regulatory cells
The T regulatory subpopulation of T lymphocytes (Treg, CD4+/CD25+/FoxP3+) consists of the natural Treg from thymus and inducible Treg (iTreg), both involved in regulation of autoimmune reaction of immune system. Extensive studies have shown the role of Treg in monitoring the immune response, especially, in control of hyperactivity leading to imbalance of immune response to pathogens and self-perpetuating inflammation process. Treg cells are important for regulation of the activity of mucous membrane associated lymphoid tissue of gastrointestinal and respiratory tracts [59-61]. The population of Treg lymphocytes in peripheral blood is assayed with flow cytometry; Treg lymphocytes localised in the tissue and in inflammatory infiltrates are detected with immunohistochemistry. The immunohistochemistry is a sensitive method commonly used for analysis of the presence, proportion and characteristics of different – not only Treg – cells, within inflammatory focuses in tissues, e.g. macrophages, T and B lymphocytes, plasma cells. The data from many indicated the central role of this T lymphocytes subpopulation in regulation of prolonged inflammatory process within mucous membrane of gastrointestinal and respiratory tracts, joints and other tissues. The analysis of Treg lymphocytes number in Leśniowski-Crohn’s disease and ulcerative colitis (UC) showed increased amount of these cells within lamina propria; whereas, the number of Treg in peripheral blood was decreased as compared to healthy people. This study of Treg cells in biopsy of intestine helped to classify the IBD patients into subgroups, based on relations between Treg number within infiltrates, clinical symptoms and course of disease. It will create specific “biological signature, ” unique to each patient, leading to individualisation of therapy (“patient tailored”) with hope for more rational therapy targeting the specific intestinal inflammatory pathway recognised in this patient [59, 62].
4. Autoimmune haematological syndromes
4.1. Thrombocytopenia acute and chronic
Thrombocytopenia associated with immunodeficiency presents two clinical forms – episodes of acute thrombocytopenia alone or as a part of Evans syndrome, with normal number of platelets in remission, and chronic thrombocytopenia, with number of platelets always below normal level [63-65]. In ALPS and WAS, thrombocytopenia is one of the criteria of a particular immunodeficiency type, so this symptom, in chronic form, is constantly present in all patients. However, the chronic form of thrombocytopenia does not exclude the exacerbations with life-threatening low numbers, or even absence of platelets. Therapy with platelets infusions, high dose of immunoglobulins and other immunosuppressive drugs (e.g. steroids, mycophenolate mofetil, sirolimus, classical drugs, rituximab) is effective; however, in majority of patients, this effect is transient. The severe clinical course of ALPS and progressing symptoms of WAS (with time) are indications for HSCT in these patients [40, 44, 45, 47, 48].
In our group of CVID patients with thrombocytopenia, all these forms (acute, chronic, exacerbations of chronic form) were noted, without relation to time of CVID diagnosis and duration. Moreover, in part of patients, thrombocytopenia was diagnosed prior to CVID onset and established diagnosis. Regular substitution of immunoglobulins in replacing dose (0.4 – 0.6 g/kg b.w. intravenously) is not effective in control of platelets number in exacerbation of chronic thrombocytopenia or prevention of acute thrombocytopenia episodes in CVID. The standard therapy of thrombocytopenia with steroids and high-dose immunoglobulins (1.0 - 2.0 g/kg b.w.) is required. Moreover, this immunoglobulins therapy is successful in majority of CVID patients, despite regular substitution of immunoglobulins in replacing dose. After infusion of immunoglobulins in high dose, the regular substitution is continued, supporting the remission of thrombocytopenia. However, there are still problems in management of thrombocytopenia in CVID – short effect of therapy for acute episodes, necessity of maintenance therapy in remission. Long-lasting remission, with normal number of platelets in CVID patients, is similar to patients without CVID, when good results are obtained with high dose of immunoglobulins and/or steroids therapy. However, in part of CVID patients, acute thrombocytopenia showed tendency to chronicity. In chronic form of thrombocytopenia with number of platelets below 100 000/ul, the regular substitution of immunoglobulins in replacing dose seemed to stabilise platelets number, without need for additional therapy, e.g. steroids or azathioprine. Clinical observations of our CVID patients with chronic thrombocytopenia showed increase of platelets number only for few days after infusion of replacing dose immunoglobulins, followed by low decrease during next 3 weeks, although, the platelets number, in nadir, was still higher than in acute episodes of thrombocytopenia. This stable, safety level of platelets, on regular substitution of immunoglobulins (replacing dose) without additional therapy of thrombocytopenia, allows patients to live normally (Table 4) .
|Diagnosis: CVID thromboc.||6 years 14 years||8 years 4 years||3 years 6 mths, 4 years 10 mths||12 years, 8 years||10 years 11 years||8 years, 7 years||5 years, 13 years|
|Main symptoms of CVID||Infections of respiratory tract, lymphadeno-
|Severe thromboc. lymphadeno-
|Thromboc. leukopenia||Thromboc.||Thromboc.||Pneumonias lymphadeno
|Laboratory data at diagnosis of CVID||Low level of IgG IgA, low number of T cells, reverse D4:CD8 ratio, weak response to vaccines||Low level of IgG, IgA, IgM, low number of T, B and NK cells||Low number
of T cells, lack
T cells to
|Low level of IgG, IgA and IgM, low number of T, B and NK cells||Low level of IgG||Low level of IgG, IgA,||Low level of IgG, IgM, lack of IgA, leukopenia, weak response to vaccines|
|Other symptoms||Mild leukopenia||leukopenia||Severe haemolytic anaemia||Severe leukopenia||no||No||Agenesis of kidney, LIP, lung fibrosis (progression), bronchiectases|
|Dose (g/kg b.w. /month) and response to IgG||0.43-0.38 good, no infections||0.36 good||0.35 – 0.42 good||0.35 – 0.45 weak (increase of platelets 2-3 days)||0.38 – 0.3 good||0.4 – 0.35 good||0.45 – 0.3 weak (low level of IgG)|
|Complications of therapy||Adverse reaction to IVIG||Severe osteoporosis, overweight, delay of puberty|
|Other therapies||Steroids before IVIG||Steroids, azathioprine (lung fibrosis) progress|
|Present status||SCIG||IVIG||No substitution, hematology
|IVIG, hematology care||No substitution, no symptoms||No substitu-
tion no symptoms
|SCIG, lungs and kidney insufficiency, splenomegaly|
|Therapy of thrombocyto-
|steroids (pulses)||IVIG 1.0g/kg b.w. steroids, azathioprine||steroids, azathioprine, IVIG 1.0 g/kg b.w.||steroids||steroids, IVIG 1.0 g/kg b.w.||steroids||steroids|
|Complications, other symptom||No||No||Severe haemolytic anaemia (Evans syndrome)||Diabetes, severe overweight||No||No|
|Lowest number of platelets (/ul)||28 000||0||0||0||27 000||20 000||37 000|
|Number of platelets at IVIG beginning||253 000||156 000||133 000||15 000||44 000||87 000||126 000|
|Mean number of platelets during IVIG (/uL)(range)||149 100
(86 000-133 000)
|Number and therapy of thromboc. exacerbations||1
IVIG 1.0 g/kg b.w. steroids
|3 (1 severe) Steroids, platelets, erythrocytes and plasma transfusions, plasmapheresis
IVIG (1.0g/kg b.w.)
|4 IVIG 1.0 g/kg b.w.||1 (severe) Steroids, splenectomy|
|Time of observation||12 years||2 years||7 years||4 years||5 years||4 years||11 years|
The regular substitution of immunoglobulins in replacing dose not only supplements specific antibodies, but also stimulates maturation of dendritic cells. This activity of immunoglobulins used in substitution was noted in XLA patients with defective dendritic cells phenotype. Similarly, defective phenotype of dendritic cells was found in CVID patients. The dendritic cells play a critical role in predisposition to pathological conditions, e.g. bacterial infections due to impaired antigen presentation and initiating the immune response, induction of autoimmunity process. Stimulation of dendritic cell maturation might be preventing the development of autoimmunity associated with defective function of these cells in immunodeficiency patients. It is believed, that regular substitution of immunoglobulins, even in replacing dose, restores the normal phenotypes of dendritic cells and their proper function .
In CVID patients demonstrating refractory thrombocytopenia, recurrent episodes of exacerbations or chronic thrombocytopenia, second-line therapy with immunosuppressive drugs like azathioprine, vincristine, cyclophosphamide and splenectomy is used [63-65]. Moreover, in CVID patients, refractory thrombocytopenia seemed to be more frequent, followed with higher ratio of indications for splenectomy, than in otherwise healthy children. Splenectomy is effective and safe in CVID patients, without higher risk of severe infections due to immunodeficiency. Moreover, the long-lasting results are similar to patients without immunodeficiency . Another therapeutic option for severe thrombocytopenia in CVID patients with normal number of B cells is monoclonal antibody against CD20 (e.g. rituximab) for elimination of B lymphocytes [68, 69]. For these patients with CVID, the risk for severe infections seemed to be higher and substitution of immunoglobulins in replacing dose should be continued every month, without decreasing the dose and/or pause, e.g. for holidays [11, 63, 64, 69]. Thrombocytopenia in CVID patients is considered as unpredictable autoimmune symptom, so a very careful clinical and laboratory monitoring is required.
4.2. Neutropenia/leukopenia, haemolytic anaemia
Neutropenia is very often associated with hyper IgM syndrome (especially in CD40L – X linked and CD40 deficiency type), leading to severe clinical course of infections, e.g. sinusitis, otitis, osteomyelitis [16, 18, 70]. In some patients, recurrent and persistent ulcers of the mucous membrane, e.g. palate, oral cavity, are noted in episodes of deep neutropenia. The symptomatic therapy is based on antibiotics/sulphonamides in prolonged course, granulocyte colony stimulating factor (G-CSF) and immunoglobulin substitution with good effect, but not in all patients. For hyper IgM patients with severe clinical course, resistance to therapy and episodes of severe bacterial or fungal infections, HSCT is recommended as curative therapy.
In CVID, leukopenia and/or neutropenia, mainly in mild form, is frequently noted. Within our group of CVID children, leukopenia was observed in few patients, but was persistent and refractory to immunoglobulins substitution and without relation to IgG level. However, due to mild clinical form, additional therapy (e.g. G-CSF for neutropenia) is required in singular cases only .
It is noted that haemolytic anaemia presents severe clinical symptoms in patients with CVID, hyper IgM, Wiskott-Aldrich syndrome and ALPS. In ALPS, the clinical course of haemolytic anaemia may be life-threatening due to severity and high frequency of episodes. Moreover, these episodes of severe anaemia cause complications, e.g. high level of iron, hepatosplenomegaly (megaspleen), poor general condition of patients. This severe clinical course of ALPS and resistance to steroids, immunoglobulins and immunosuppression therapy are an indication for HSCT as life-saving procedure . Moreover, for patients with milder course of ALPS, symptomatic therapy with good response and careful monitoring of blood parameter are satisfactory.
5. Involvement of the gastrointestinal tract in primary immunodeficiency
5.1. Celiac disease
Celiac disease diagnosed as latent, silent or atypical form, in children older than infants, comprises about 80% of total number of celiac paediatric patients. The clinical symptoms in atypical form of disease are discrete or unspecific, so the diagnosis is often delayed. Moreover, there have been more than 200 symptoms reported in association with gluten sensitivity, which does not facilitate establishing proper, early diagnosis . Low levels of iron, resistant to oral therapy, vitamins (e.g. vit. D), calcium, zinc and other minerals deficiency are symptoms suggesting jejunum dysfunction (malabsorption), typical for celiac disease in children and teenagers . The clinical symptoms of celiac disease may be unspecific (e.g. underweight, inhibition of growth, afts), delicate and overlapping with symptoms characteristic of immunodeficiency (IgAD, CVID without IgA), like abdomen pain, episodes of diarrhoea, chronic diarrhoea, food allergy [72, 73]. The co-existence of IgAD and celiac disease (frequency of celiac disease within IgAD patients is 10–20 times higher than in healthy children) supported the idea of the common genetic background for these two diseases. The study indicated the ancestral haplotype HLA-A1, Cw7, B8, DR3, DQ2 as important for this association of two diseases. However, the frequency of celiac disease within IgAD population is still lower, than expected, based on common genetic background, so this hypothesis remains without confirmation . The other explanation is based on persistent stimulation of immune system associated with mucous membrane, by gluten and gliadin in absence of IgA, which leads to the damage of jejunum and onset of clinical symptoms. Stimulation of immune system, including B lymphocytes, was represented by increased expression of B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) in patients with IgAD and celiac disease, although, the difference between IgAD patient with and without celiac disease was non-significant. Stimulation of B lymphocytes (increased APRIL level) might be important for compensatory local production of IgG and IgM . The number of T lymphocytes TCR γ/δ infiltrating epithelial cells (IEL) was higher in IgAD patients than in healthy people, but lower than number of IEL TCR γ/δ noted in IgAD with co-existent celiac disease .
5.2. Leśniowski-Crohn’s disease and ulcerative colitis
Chronic diarrhoea as typical clinical symptom of gastrointestinal involvement is seen in a wide range of adult patients (10–50%) with CVID [8, 27, 55, 76]. In children with CVID and IgAD, chronic diarrhoea is much less frequent, but clinical data are based on relatively small number of patients. In IgAD children, the IBD was noted sporadically, with clinical course similar to children without IgAD. In CVID patients, the IBD remains a significant problem for 19–32% of patients . In adults with Leśniowski-Crohn’s disease and CVID, besides typical changes of intestine wall and surface, the formation of granulomas is noted. Furthermore, the substitution of immunoglobulins does not inhibit and/or reverse the symptoms of chronic colitis [77, 78]. A variety of explanations are proposed, but the hypothesis that IgG from immunoglobulin preparations are not able to reach the epithelium of intestine, even intact, seems to be interesting. It might explain higher incidence of small bowel inflammation, with severe and progressing course, especially in patients with CVID without IgA, treated with regular immunoglobulins substitution in replacing dose. The other possible mechanisms explaining the differences in Leśniowski-Crohn’s course between CVID patients and healthy people are associated with Treg defects, inflammation supported by activated T lymphocytes, and different list of cytokines produced locally within intestine wall . The role of T lymphocytes is postulated based on different histology of infiltrates within wall of small intestine in CVID. The main difference in proportion between T and B lymphocytes within infiltrates is lack of plasmocytes. The remaining phenomena, e.g. the villi flattening, increased number of IEL and lymphocytes in lamina propria, and increased epithelial apoptosis, were observed in CVID patients similar to patients without CVID [27, 77, 78]. The distinct pathway of inflammation in CVID depends also on cytokine profile, when the production of IL-23, IL-17 and TNF is lower in CVID than in Leśniowski-Crohn’s patients without CVID .
5.3. Autoimmune hepatitis
The exact aetiology of autoimmune hepatitis, similar to other autoimmune diseases, is unknown, but viral infections, especially hepatotropic, and drugs may be the trigger. In etiopathology, the immunological mechanisms involved the function of Treg cells, IgA defence against gastrointestinal pathogens, including viruses [79, 80]. In adult patients with CVID, autoimmune chronic hepatitis is noted in about 10% . The study of autoimmune paediatric liver disease showed association between IgAD and autoimmune hepatitis type 2 with slower progression to cirrhosis than in hepatitis type 1 . This association might facilitate autoimmune hepatitis in patients with IgAD and CVID with low IgA. In patients with hyper IgM syndrome (mainly X-linked), typical liver involvement is associated with
5.4. Other autoimmune diseases in patients with immunodeficiency
In adult patients diagnosed with CVID, the autoimmunity presented a different pattern as compared to children. Rheumatoid arthritis, systemic lupus erythematodes are more frequent than gastrointestinal tract disease; however, the haematologic symptoms are equally frequent in children and adult CVID patients [27, 82]. Rheumatoid arthritis is noted in hyper IgM patients and, what seemed unusual, in X-linked agammaglobulinemia [83, 84]. The explanation of this phenomenon is based on detection of small population of immature B cells in peripheral blood. These B cells are often autoreactive, which suggests that the central and peripheral mechanisms of tolerance have failed . One of our boys with XLA developed eosinophilic fasciitis of right crus, with poor response to immunoglobulins in high dose and non-steroidal anti-inflammatory drugs. Now, the improvement was obtained with steroids in high dose (intravenous pulses), followed with steroids in maintenance dose and MTX in prolonged therapy. However, immunosuppression with MTX was complicated with pneumonia (twice) due to XLA, so MTX was changed to mycophenolate mofetil with good response and hope for fewer side effects and better tolerance by immune system. The partial remission (mild symptoms without pain) obtained with MTX continues and, now, the boy is attending school normally, extra effort being the only limitation.
6. Diagnosis and management of primary immunodeficiency with autoimmunity
6.1. Substitution of immunoglobulins
The main goal of regular substitution of immunoglobulin IgG (intravenous or subcutaneous) in X-linked agammaglobulinemia, hyper IgM syndrome and CVID is supply of the specific antibodies. The immunoglobulins, mainly IgG with trace of IgA witout IgM, are separated and purified from serum of healthy blood donors. The antibodies, important for immunodeficient patients, are active against common pathogens and vaccines antigens, so they are able to prevent infections, but with spectrum of common pathogens. The regular substitution of immunoglobulins should be provided according to standard indications for patients with low but basic levels of IgG in serum. The substitution for XLA, hyper IgM patients, in first moment after diagnosis is individualised depending on clinical state and present infections. For patient without infections, but with IgG level below detection, intravenous substitution (IVIG) should be introduced in higher dose (e.g. 0.75 g/kg b.w.) in 2 weeks period, up to the safety level of IgG in patient’s serum (5.0–5.5 g/l). The standard schedule of IVIG is based on half-life of IgG (21–24 days), so the dose 0.4– 0.6 g/kg b.w. is regularly infused every month. The clinical observations of effects of immunoglobulins substitution showed the 6–8 months period as time required for patient’s stabilisation (“steady state”). However, in some CVID patients, obtained IgG level within normal value for age is not enough to prevent recurrent infections. For these patients, the “through level” is used as indication for individualised dose of immunoglobulins substitution [27, 39, 77, 85-87]. The modifications of IVIG includes shorter time between the infusion or higher level in singular infusion, due to bacterial infections, wound healing or other causes leading to overconsumption of immunoglobulins. In XLA without infections, the lower dose (0.2–0.3 g/kg b.w.) in longer period (e.g. 6 weeks) may be used. Moreover, adults with complications like chronic lung disease, chronic sinusitis or gastrointestinal disease may require the individual schedule of substitution (“patient-tailored therapy”). These modifications are based not only on clinical patient status, but on careful, precise monitoring of IgG level . The immunoglobulins offered as substitution should prevent the occurrence of infections, at least, to decrease their frequency, soften the clinical course and improve the response to therapy. Moreover, the regular substitution of IgG in replacing dose, seemed to be effective (stabilising) in chronic thrombocytopenia and chronic neutropenia in some patients with this type of autoimmunity . This effect is probably associated with anti-inflammatory activity of IgG, even in replacing dose, although, the precise mechanisms are not described. One interesting observation showed the activation of monocytes subpopulation in patients with CVID after immunoglobulins infusion in replacing dose . It might be that the regular, long-term continued substitution may lead to accumulation of small, repeated effects of IgG, resembling the anti-inflammatory activity of this immunoglobulin in low replacing dose. The mechanisms responsible for anti-inflammatory activity of IgG preparations used in high dose of immunoglobulins (1.0–2.0 g/kg b.w.) for autoimmune diseases therapy (e.g. acute thrombocytopenia, Kawasaki disease, Guillain-Barre syndrome, myasthenia crisis) are well defined and mainly based on regulatory activity [27, 86, 89].
The adverse reactions of IVIG may occur immediately, during the infusion or after, up to 4 days. The symptoms of adverse reactions are mild or severe, including anaphylactic shock as most severe reaction, occurring often very quickly, after few drops of immunglobulins’ solution. Fever, chills, pain (headache, abdominal pain) and cough are noted in children as mild symptoms resolved with appropriate symptomatic therapy. The late, severe reactions are the consequence of immunoglobulins distribution into tissues, especially into central nervous system. Severe and progressive headache, vomiting, disturbances of vision, speech and balance are neurological symptoms typical for this reaction. Intensive hydration (decrease of IgG level, filling the vessels) and steroids (anti-oedematic activity) given intravenously are effective as therapy [77, 90, 91]. In case of severe adverse reactions, the subcutaneous way of immunoglobulins substitution (SCIG) is recommended. The amount of immunoglobulins given monthly is divided in four portions (0.1– 0.2 g/kg b.w. per week), administered with special pump in children or with syringe only (“rapid push”) in adults. The effectiveness of SCIG is similar to IVIG, but the adverse reactions are very rare and limited to the place of injection. SCIG is a form of home therapy, very comfortable for patients, offering independence from hospital. In XLA, CVID diagnosed in adults, hyper IgM syndrome, the regular substitution of immunoglobulins is for life, so the SCIG form of immunoglobulins substitution is preferred for these patients avoiding the pain associated with poor vein access after years of IVIG. The exception from indication for “substitution for life” is patients with X-linked hyper IgM syndrome treated with HSCT [92-94]. In children with CVID, the developing immune system gives the opportunity to hang off the substitution after reaching the stable, normal level of IgG, low frequency of infections with good response to therapy, resembling the immune system maturation.
6.2. Symptomatic therapy and prophylaxis of infections
In part of children with CVID, the effect of regular immunoglobulins substitution (IVIG or SCIG) is weak and infections, mainly in respiratory tract, are still present. With time, in some of these patients, the lymphocytic interstitial pneumonia (LIP, or GLILD – granulomatous lymphocytic insterstitial lung disease), chronic sinusitis and bronchiectases develop, progressing lung fibrosis and persistent leukopenia (neutropenia) are noted, so prophylaxis with antibiotics is recommended. The 3–4 months’ period of antibiotics or time-to-prime in prophylactic dose is commonly used as effective schedule of supportive therapy, improving clinical status of patients. However, the therapy with antibiotics is still a matter of discussion and different approaches to this therapy are suggested depending on clinical centre and severity of patients’ symptoms. The specific and unique recommendation for antibiotics prophylaxis is aimed at prevention of endocarditis following invasive procedures in immunodeficient patients . In our clinical management of more than 200 immunodeficient patients, such complication was not observed, but because of the severity of this symptom, prophylaxis should be considered.
6.3. Monitoring and therapy of co-existent autoimmunity
Therapy of common autoimmune diseases, e.g. thrombocytopenia, neutropenia, haemolytic anaemia, in patients with immunodeficiency is based on standard therapy of such symptoms; the use of immunoglobulins in high dose, steroids, immunosuppression with methrotrexate, vincristine, azatioprine, but special therapy is required for some of immunodeficient patients. In ALPS, the use of sirolimus is suggested, as possibility to induce apoptosis, helping in elimination of double-negative T lymphocytes. Sirolimus is preferentially used in these patients for resolving symptoms (e.g. lymphadenopathy, splenomegaly) and diminish the severity of clinical course. The expected effect of sirolimus is to diminish the spleen volume (megaspleen), one of most danger symptom in children with ALPS [44-47].
The therapeutic approach to immunodeficient patients with Leśniowski-Crohn’s disease is generally similar to therapy of patients without immunodeficiency; although, inflammation process in CVID might be resistant to therapy. In these patients, the process of intestine inflammation is active despite immunosuppression (e.g. azathioprine, cyclosporine) used as second line of therapy, after systemic steroids, budesonite and anti- inflammatory non-steroidal drugs without remission. Therapy with the monoclonal antibodies against TNF (infliximab, etanercept) is effective in inductions the remission in patients with immunodeficiency, similar to patients without immunodeficiency. However, CVID patients are more prone to infections during such therapy, so very careful monitoring of this group of patients is recommended, not only for bacterial, but fungal and viral infections, due to defects of T lymphocyte function .
The frequency of UC in CVID and IgAD patients is not known, but it seems that in children it is even less frequent than in adult CVID and IgAD patients. In a large group of CVID patients (248 children and adults), UC was noted in 7 patients; however, the unspecific significant malabsorption symptoms were observed in other10 patients . It shows the problem of overlapping symptoms, difficulties in establishing the precise diagnosis and requirement for wide differential diagnostic procedures performed in these patients .
7. Progress in therapy of autoimmunity
7.1. Indications for monoclonal antibodies
Monoclonal antibodies are used for elimination of target cell population, cytokine or blocking of determinants on cell surface. Humoral immune deficiency is based on B-cell intrinsic deficiency and disturbances of B-cell ontogeny. Autoimmunity in patients with very low number of B lymphocytes is associated with relatively high number of autoreactive B cells within this small B-cell population. Following this hypothesis of autoimmunity in humoral immunodeficiency, the therapy with monoclonal antibodies against B lymphocytes seems to be logical and reasonable. Use of rituximab (monoclonal antibody against CD20 determinant restricted to mature B lymphocytes) in autoimmune cytopenias in CVID, ALPS and hyper IgM syndrome (as alternative to HSCT) was successful [19, 44, 45, 95].
The therapy of autoimmune diseases characterised by chronic inflammatory process (SLE, rheumatoid arthritis, IBD) with important role of cytokines and T lymphocytes includes monoclonal antibodies against cytokines (TNF), IL-2 receptor on T lymphocytes (CD25 as activation marker) and others. Within CVID patients, celiac disease is often refractory to GFD (RCD), leading to malabsorption syndrome and severe clinical conditions [11, 27, 96, 97], which suggests different mechanism present in these patients. Careful observation and studies showed different forms: type I with T lymphocytes with normal phenotype (expression of CD3 and CD8 determinants, normal polyclonal T-cell receptor (TCR) arrangement) and type II with aberrant T lymphocyte phenotype, intracellular presence of CD3, monoclonal TCR rearrangement [8, 96, 98]. Type II of progressing celiac disease in spite of GFD and some cases of Crohn-like disease are associated with poor prognosis with increased mortality, due to progressing malabsorption syndrome and T-cell lymphoma in reasonable number of such patients [77, 96]. After standard therapy without effect, the second-line therapy with immunosuppression (azathioprine) and/or monoclonal antibodies against TNF (infliximab, etanercept, humira) is required for patients with active, progressive disease .
7.2. Suppressive therapy
The first line of immunosuppressive therapy in patients with or without immune deficiency includes steroids, in individual doses, for all autoimmune symptoms and diseases. For cytopenias, especially thrombocytopenia, the schedule with high doses of steroids given intravenously every month (“pulses”) is often used to increase the number of platelets. Chronic thrombocytopenia is controlled with maintenance dose of steroids, but the side effects of steroids are the main limitation for this therapy. The second-line therapy includes typical immunosuppressants, e.g. azathioprine, metotrexate, vincristine, cyclophophamide, cyclosporine A. In ALPS, sirolimus and mycophenolate mofetil are suggested, with good clinical response in majority of patients. Moreover, this therapy is well tolerated, without severe side effects, even in infants and babies with ALPS. Regular substitution of immunoglobulins (recommended in intravenous form) is important to diminish the risk of infections associated with prolonged immunosuppression [7, 77, 78, 95].
7.3. Indications for haematopoietic stem cells transplantation (HSCT)
Historically, the first group of patients who underwent HSCT as a life-saving and curative therapy were newborn babies diagnosed with SCID. The following group of patients transplanted with HSCT were children with X-linked immunodeficiency, e.g. hyper IgM syndrome, WAS, chronic granulomatous diseases (CGD) [100-104]. The increasing number of children cured from SCID, improvement of transplantation procedure (low risk factor) and post-transplant care, is encouraging transplantologists and immunologists to offer this therapy for patients with other types of primary immunodeficiency. Now, patients with ALPS, X-linked lymphoproliferative diseases, haemophagocytic lymphohistiocytosis are transplanted in increasing numbers . Successful HSCT in SCID patients, after matched donor transplant, in Europe is 90% survival; non-SCID immunodeficiency patients – about 80%, which means real, great progress in treatment of patients with severe clinical forms of immunodeficiency .
The hyper IgM syndrome, ALPS, Wiskott-Aldrich syndrome may represent mild clinical course with satisfactory symptomatic therapy, so HSCT is not a first-line therapy. The indications for HSCT in these patients are based on severe clinical course, progress of symptoms associated with immunodeficiency leading to poor prognosis for life [47, 100-104]. The symptomatic therapy in these syndromes include steroids for severe autoimmunity symptoms, regular substitution of immunoglobulins, antibiotics and antimycotic drugs as prophylaxis, and treatment for existent bacterial, fungal and viral infections. This therapy is necessary up to the time of HSCT, as good clinical state of patient decreases the risk of complications after HSCT. The CVID with typical clinical course is not an indication for HSCT, due to satisfactory effects of symptomatic therapy, much more save, than HSCT. However, in individual cases with progressing, severe complications, like RCD, IBD, leading to malnutrition, this procedure is recommended . Within our CVID children, HSCT was performed with success in girl with severe malnutrition due to malabsorption in celiac disease resistant to GFD. She was treated for few years with restricted GFD, antibiotics, steroids, anti-TNF monoclonal antibodies, immunosuppression (cyclosporin A) without effect, so HSCT was the life-saving procedure. HSCT was performed in our 3 patients (children below age of 3 years) with severe course of ALPS, when therapy with steroids, immunoglobulins, mycophenolate mofetil and sirolimus was without long-lasting remission and progression of the autoimmune symptoms .
8. Other problems
8.1. Granulomatous and lymphocytic interstitial lung disease (GLILD) – autoimmunity or not
GLILD (former name – lymphoid interstitial pneumonia) is a rare clinical entity with unknown aetiology and pathophysiology. The diffuse infiltration of lymphoid cells localised mainly in the interstitial tissue is a typical histopathological feature. LIP is typically associated with autoimmunity, e.g. Sjogren syndrome, autoimmune thyroid disease, SLE, but also with immunodeficiency, mainly CVID and AIDS [105, 106]. LIP is noted in about 10% of CVID patients, which could indicate the association between these clinical features. This type of interstitial pneumonia is an independent factor of poor prognosis with negative impact on the survival of patients due to lung fibrosis, followed by recurrent episodes of pneumonia with infiltrations. Clinical symptoms of GLILD overlap with chronic bronchitis or bronchiectases, signalled by prolonged cough. Moreover, the regular substitution of immunoglobulins, in replacing dose, is not effective in prevention and resolving of these lung symptoms. Therapy included prolonged steroids and/or immunosuppression (azathioprine, cyclophosphamide) in individual combination, depending on patient immune system and clinical symptoms. Prolonged therapy with steroid or immunosuppression is difficult in CVID patients, due to increased risk of infections, potentiating of leukopenia/neutropenia and thrombocytopenia. Among our patients with CVID, treated with regular substitution of immunoglobulins, LIP was noted in 3 children. The clinical course of CVID was severe due to RCD in girl (later on transplanted with HSCT), leukopenia (neutropenia) and thrombocytopenia in both boys. Moreover, one of these boys diagnosed with LIP, demonstrated hepatomegaly, splenomegaly and lymphadenopahty localised in lungs hilus and in mesenterium. Therapy of LIP included, in first line, only steroids, followed by azathioprine (because of severe adverse reaction after steroids and lack of effect), with good results in second boy. The resolving of LIP symptoms was slow, taking 2–3 years of immunosuppressive therapy and regular substitution of immunoglobulins in 0.5g/kg b.w. The frequency of infections during this therapy was not higher, but the course of the few infections that occurred was prolonged, requiring antibiotic therapy.
9. Conclusions and general remarks
Autoimmune diseases are a large group of heterogeneous diseases characterised by an unpredictable course with variable response to immunosuppressive therapy, from very good (long-lasting remission), to poor with progression of severe and life-threatening symptoms. Autoimmune diseases in immunodeficiency syndromes can develop prior or after the onset of immunodeficiency, during the regular substitution of immunoglobulins.
The management of patients with autoimmunity associated with immunodeficiency is more difficult than patients without immunodeficiency due to various reasons: the production of autoantibodies, the generally used marker of autoimmunity, is weaker in immunodeficiency; the clinical symptoms may overlap with basic symptoms of immunodeficiency; the response to therapy is often poorer than in patients without immunodeficiency. The level of autoantibodies, below limit of positive results, due to immunodeficiency, should be considered as significant for diagnosis of autoimmune disease in PID. The interpretation of laboratory results in these patients need very careful and different attitude than usual. The resistance to therapy, severe, and progressing symptoms of autoimmunity, as complication of immunodeficiency (e.g. CVID, ALPS) are the indications for HSCT as life-saving procedure.
I would like to thank our immunologists’ team (Prof. Danuta Kowalczyk, Prof Maciej Siedlar, Dr Anna Szaflarska, Dr Anita Błaut-Szlósarczyk, Dr Katarzyna Zwonarz) for taking care of our patients with primary immunodeficiencies and transplantologists’ team (Prof. Assist, Jolanta Goździk, Prof Assist. Szymon Skoczeń, Dr. Aleksandra Krasowska-Kwiecień, Dr Agnieszka Dłużniewska) for closed cooperation and help in saving our patients’ life with HSCT procedure.
Al-Herz W, Bousfiha A, Casanova J-L, Chapel H, Conley ME, Cunningham-Rundles Ch, Etzioni A, Fischer A, Franco JL, Geha RS, Hammarstrom L, Nonoyama S, Notaranghelo LD, Ochs HD, Puck JM, Roifman ChM, Seger R, Tang MLK (2011) Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for primary immunodeficiency. Front Immunol. 2; art. 54.
Bousfiha AA, Jeddane L, Ailal F, Al Herz W, Conley ME, Cunnigham-Rundles Ch, Etzioni A, Fischer A, Franco JL, Geha RS, Hammastrom L, Nonoyama S, Ochs HD, Roifman ChM, Seger R, Tang MLK, Puck JM, Chapel H, Notarangelo LD, Casanova J-L (2013) A phenotypic approach for IUIS PID classification and diagnosis: guidelines for clinicians of the bedside. J Clin Immunol. 33; 1078-1087.
Chinen J, Notarangelo LD, Shearer WT (2013) Advances in basic and clinical immunology in 2012. J Allergy Clin Immunol. 131; 675-682.
Coutinho A, Carneiro-Sampaio M (2008) Primary immunodeficiencies unravel critical aspects of the pathophysiology of autoimmunity and of the genetic in autoimmune disease. J Clin Immunol. 28; suppl.1, S4-S10.
Notarangelo LD, Fischer A, Geha RS, Casanova J-L, Chapel H, Conley ME, Cunningham-Rundles Ch, Eztioni A, Hammarstrom L, Nonoyama S, Ochs HD, Puck J, Roifman Ch, Seger R, Wedgwood J (2009) Primary immunodeficiencies: 2009 update. J Allergy Clin Immunol124; 1161-1678.
de Vries E, Driessen G (2011) Primary immunodeficiencies in children: a diagnostic challenge. Eur J Pediatr170; 169-177.
Arkwright PD, Abinun M, Cant AJ (2002) Autoimmunity in human primary immunodeficiency diseases. Blood. 99; 2694-2702.
Agarwal S, Cunningham-Rundles C (2009) Autoimmunity in common variable immunodeficiency. Curr Allergy Asthma Rep. 9; 347-352.
Oksenhendler E, Gerard L, Fieschi C, Malphettes M, Moulliot G, Jaussaud R, Viallard J-F, Gardembas M, Galicier L, Schleinitz N, Suarez F, Soulas-Sprauel P, Hachulla E, Jaccard A, Gardeur A, Theodorou I, Rabian C, Debre P (2008) Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis. 46; 1547-1554.
Arason GJ, Jorgensen GH, Ludviksson BR (2010) Primary immunodeficiency and autoimmunity. Scand J Immunol. 71; 317-328.
Cunningham-Rundles Ch (2011) Autoimmunity in primary immune deficiency: taking lessons from our patients. Clin Exp Immunol. 164: 6-11.
Schroeder HW, Szymańska-Mroczek E (2013) Primary antibody deficiencies. In: Fourth Edition Clinical Immunology. Eds: Rich RR, Fleicher TA, Shearer WT, Schroeder HW, Frew AJ, Weyand CM. Elsevier. pp. 421-436.
Bao Y, Zheng J, Han Ch, Jin J, Han H, Liu Y, Lau Y-L, Tu W, Cao X (2012) Tyrosine kinase btk is required for NK cells activation. J Biol Chem.287; 23769-23778.
Pituch-Noworolska A, Zwonarz K, Błaut-Szlósarczyk A, Szaflarska A, Kowalczyk D, Siedlar M (2013) T lymphocytes and NK cells in X-linked agammaglobulinemia. Przegl Lek70; 1048-1050.
Ochs HD, Smith C (1996) X-linked agammaglobulinemia. Medicine (Baltimore)75; 287-299.
Notarangelo LD, Hayward AR (2000) X-linked immunodeficiency with hyper IgM (XHIM). Clin Exp Immunol. 120; 399-405.
Pituch-Noworolska A, Kowalczyk D, Macura-Biegun A, Szaflarska A (2007) The clinical features of hyper-IgM syndrome. Centr Eur J Immunol. 32; 105-112.
Davies EG, Thrasher AJ (2010) Update on the hyper immunoglobulin M syndrome. Brit J Haematol. 49; 167-180.
Hennig Ch, Happle Ch, Hansen G (2011) “A bad wound may heal, but a bad name can kill” – lessons learned from “hyper IgM syndrome”. J Allergy Clin Immunol. 128; 1380-1382.
Aghamohammadi A, Cheragi T, Gharagozlou M, Movahedi M, Rezaei N, Yeganeh M, Parvaneh N, Abolhassani H, Pourpak Z, Moin M (2009) IgA deficiency: correlation between clinical and immunological phenotypes. J Clin Immunol. 29; 130-136.
Fried AJ, Bonilla FA (2009) Pathogenesis, diagnosis, and management of primary antibody deficiencies and infections. Clin Microbiol Rev. 22; 396-414.
Yel L (2010) Selective IgA deficiency. J Clin Immunol. 30; 10-16
Notarangelo LD (2009) Primary immunodeficiencies (PIDs) presenting with cytopenias. Hematology Am Soc Hematol Educ Program.139-144.
Vale AM, Schroeder HW (2010) Clinical consequences of defects in B-cell development. J Allergy Clin Immunol. 125; 78-787.
Jacob CMA, Pastorino AC, Fahl K, Carneiro-Sampaio M, Monteiro RC (2008) Autoimmunity in IgA deficiency. J Clin Immunol. 28; S56-S61.
Cunningham-Rundles Ch, Bodian C (1999) Common variable immunodeficiency. Clin Immunol. 92; 34-48.
Cunningham-Rundles Ch (2010) How I treat common variable immune deficiency. Blood. 116; 7-15.
Chapel H, Cunningham-Rundles Ch (2009) Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Brit J Haematol. 145; 709-727.
Glocker E, Ehl S, Grimbacher B (2007) Common variable immunodeficiency in children. Curr Opin Pediatr. 19; 685-692.
Llobet MP, Soler-Palacin P, Detkova D, Hernandez M, Caragol I, Espanol T (2009) Common variable immunodeficiency: 20-years experience at a single centre. Pediatr Allergy Immunol. 20; 113-118.
Urschel S, Kaykci L, Wintergerst U, Nothes G, Jansson A, Belochradsky BH (2009) Common variable immunodeficiency disorders in children: delayed diagnosis despite typical clinical presentation. J Pediatr. 154; 888-894.
Alachkar H, Taubenheim N, Haenay MR, Dyrandy A, Arkwright PD (2006) Memory switched B cell percentage and not serum immunoglobulin concentration is associated with clinical complications in children and adults with specific antibody deficiency and common variable immunodeficiency. Clin Immunol. 120; 310-318.
Huck K, Feyen O, Ghost S, Beltz K, Bellert S, Niehues T (2009) Memory B-cells in healthy and antibody deficient children. Clin Immunol. 131; 50-59.
Notarangelo LD (2010) Primary immunodeficiencies. J Allergy Clin Immunol. 125, S182-S194.
Wehr C, Kivioja T, Schmitt Ch, Ferry B, Witte T, Eren E, Vlkova M, Hernandez M, Detkova D, Bos PR, Poerksen G, von Bernuth H, Baumann U, Goldacker S, Gutenberger S, Schlesier M, Bergeron-van der Cruyssen F, Le Garff M, Debre P, Jacobs R, Jones J, Bateman E, Litzman J, van Hagen PM, Plebani A, Schmidt RE, Thon V, Quinti I, Espanol T, Webster AD, Chapel H, Vihinen M, Oksenhendler E, Peter HH, Warnatz K (2008) The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood. 111; 77-85.
Warnatz K, Voll RE (2012) Pathogenesis of autoimmunity in common variable immunodeficiency. Front Immunol. 3; art. 210.
Chase NM, Verbsky JW, Hintermeyer MK, Waukau AT, Casper JT, Singh S, Shahir KS, Tisol WB, Nugent ML, Rao NR (2013) Use of combinations chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency. J Clin Immunol. 33; 30-39.
Gathmann B, Mahlaoui N, Gerard L, Oksenhendler E, Warnatz Kschulze I, Kindle G, Kuijpers TW, van Beem RT, Guzman D, Workman S, Soler-Palacin P, De Gracia J, Witte T, Schmidt RE, Lizman J, Hlavackova E, Thon V, Borte M, Borte S, Kumararatne D, Feighery C, Longhurst H, Helbert M, Szaflarska A, Sediva A, Belohradsky BH, Jones A, Baumann U, Meyts I Kutukculer N, Wagstrom P, Galal NM, Roesler J, Farmaki E, Zinovieva N, Ciznar P, Papadopoulou-Alataki E, Bienemann K, Velbri S, Pnahloo Z, Grimbacher B for the European Society for Immunodeficiencies Registry Working Party (2014): Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol. 133: 1-11.
Bethune CA, Spickett GP (2000) Common variable immunodeficiency. BioDrug. 13; 243-253.
Catucci M, Castiello MC, Pala F, Bosticardo M, Villa A (2012) Autoimmunity in Wiskott-Aldrich syndrome. Front Immunol. 3; art. 209.
Park JY, Kob M, Prodeus AP, Rosen FS, Shcherbina A, Remold-O’Donnell E (2004) Early deficit of lymphocytes in Wiskott-Aldrich syndrome: possible role of WASP in human lymphocytes maturation. Clin Exp Immunol.136; 104-110.
Ochs HD (1998) The Wiskott-Aldrich syndrome. Semin Hematol. 35; 332-345.
Albert MH, Notarangelo LD, Ochs HD (2011) Clinical spectrum, pathophysiology and treatment of the Wiskott-Aldrich syndrome. Curr Opin Hematol. 18; 42-48
Rao VK, Oliveira JB (2011) How I treat autoimmune lymphoproliferative syndrome. Blood. 118; 5741-5751
Teachey DT, Seif AE, Grupp SA (2009) Advances in management and understanding of autoimmune lymphoproliferative syndrome (ALPS). Brit J Haematol. 148; 205-216.
Kwon S-W, Procter J, Dale JK, Strus SE, Stroncek DF (2003) Neutrophil and platelets antibodies in autoimmune lymphoproliferative syndrome. Vox Sanguinis. 85; 307-312.
Szaflarska A, Pituch-Noworolska A, Błaut-Szlósarczyk A, Zwonarz K (2013) Autoimmune lymphoproliferative syndrome (ALPS) in infants – indications and effects of sirolimus therapy. First International Primary Immunodeficiency Congress, 7-8.11.2013 Estoril, Portugal.
Rieux-Laucat F, Blanchere S, Danielan S, de Villartay JP, Oleastro M, Solary E, Bader-Maunier B, Arkwright P, Pondare C, Bernaudin F, Chapel H, Nielsen S, Berrah M, Fischer A, le Diest F (1999) Lymphoproliferative syndrome with autoimmunity. Blood. 94; 2575-2582.
Elkon K, Casali P (2008) Nature and function of autoantibodies. Nat Clin Pract Rheumatol. 4; 491-498.
Lindfors K, Kaukinen K (2012) Contribution of celiac disease autoantibodies to the disease process. Expert Rev Clin Immunol. 8; 151-154.
Ardesjo B, Portela-Gomez GM, Rorsman F, Gerdin E, Loof L, Grimelius L, Kampe O, Ekwall O (2008) Immunoreactivity against goblet cells in patients with inflammatory bowel disease. Inflamm Bowel Dis. 14; 652-661.
Bogdanos DP, Rigopoulou EI, Smyk DS, Roggenbuck D, Reinhold D, Forbes A, Laass MW, Conrad C (2011) Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn’s disease specific-pancreatic autoantibodies. Autoimmun Rev. 11; 143-148.
Papp M, Norman GL, Altorjay I, Lakatos PL (2007) Utility of serological markers in inflammatory bowel diseases: gadget or magic? World J Gastroenterol. 14; 2028-2036.
Malamat G, Verkarre V, Suarez F, Viallard J-F, Lascaux A-S, Cosnes J, Bouhnik Y, Lambotte O, Bechade D, Ziol M, Lavergne A, Hermine O, Cerf-Bensussan N, Cellier C 0(2010) The enteropathy associated with common variable immunodeficiency. Am J Gastroenterol. 105; 2262-2275.
Agarval S, Smereka P, Harpaz N, Cunnigham-Rundles Ch, Mayer L (2011) Characterization of immunologic defects in patients with common variable immunodeficiency (CVID) with intestinal disease. Inflamm Bowel Dis. 17; 251-259.
Pituch-Noworolska A, Zwonarz K (2012) Celiac and inflammatory bowel diseases in children with primary immunodeficiency. In: Autoimmune Disease. Ed. Chan J, InTech, chapter 7, pp. 151-172.
Al-Muhsen SZ (2010) Gastrointestinal and hepatic manifestations of primary immune deficiency diseases. Saudi J Gastroenterol. 16; 66-74.
Walker MM, Murray JA (2011) An update in the diagnosis of celiac disease. Histopathology. 59; 166-179.
Schirbel A, Fiocchi C (2010) Inflammatory bowel disease: established and evolving considerations on its etiopathogenesis and therapy. J Digest Dis. 11; 266-276.
Glocker E, Grimbacher B (2012) Inflammatory bowel disease. Cell Mol Life Sci. 69; 41-48.
Genre J, Errante PR, Kokron CM, Toledo-Barros M, Camara NOS, Rizzo LV (2009) Reduced frequency of CD4+CD25highFoxP3+ cells and diminished FoxP3 expression in patients with common variable immunodeficiency: a link to autoimmunity? Clin Immunol. 132; 215-221.
Kaser A, Zeissig S, Blumberg RS (2010) Inflammatory bowel disease. Ann Rev Immunol. 28; 573-621.
Wang J, Cunningham-Rundles C (2005) Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID). J Autoimmun. 25: 57-62.
Michel M, Chanet V, Galicier L, Ruivard M, Levy Y, Hermine O, Oksenhendler E, Schaeffer A, Bierling P, Godeau B (2004) Autoimmune thrombocytopenic purpura and common variable immunodeficiency. Medicine. 83: 254-263.
Cunningham-Rundles Ch (2002) Hematologic complications of primary immune deficiencies. Blood Rev. 16; 61-64.
Pituch-Noworolska A, Siedlar M, Kowalczyk D, Szaflarska A, Błaut-Szlósarczyk A, Zwonarz K (2014) The effect of immunoglobulins substitution in common variable immunodeficiency (CVID) with chronic thrombocytopenia. Congress of Polish Society of Clinical and Experimental Immunology, 24-26 June, Wrocław, Poland.
Kaveri SV, Maddur MS, Hadge P, Lacroix-Desmazes S, Bayry J (2011) Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin Exp Immunol. 164: 2-5.
Al-Ahmad M, Al-Rasheed M, Al-Muhadi A (2010) Successful use of rituximab in refractory idiopathic thrombocytopenic purpura in a patient with common variable immunodeficiency. J Investig Allergol Clin Immunol. 20: 259-262,
Gobert D, Busel JB, Cunningham-Rundles C, Galicier L, Dechartes A, Berezne A, Bonnotte B, DeRevel T, Auzary C, Jaussaud R, Larroche C, LeQuellec A, Ruivard M, Seve P, Smail A, Viallard J-F, Godeau B, Hermine O, Mechel M (2011) Efficacy and safety of rituximab in common variable immunodeficiency-associated cytopenias: a retrospective multicentre study of 33 patients. Brit J Haematol. 155: 498-508.
Pituch-Noworolska A (2014) The effect of immunoglobulins substitution in hyper IgM syndrome. 7th International Immunoglobulins Conference 4-5 Apr, Interlaken, Switzerland.
Sokolic R (2013) Neutropenia in primary immunodeficiency. Curr Opin Hematol. 20; 55-65
Nejad AR, Rostami K, Pourhoseingholi MA, Mojarad EN, Habibi M, Dabiri H, Zali Mr (2009) Atypical presentation is dominant and typical for celiac disease. J Gastrointestin Liver Dis. 18; 285-291.
Valletta E, Fornaro M, Pecori S, Zanoni G (2011) Selective immunoglobulin A deficiency and celiac disease. J Invest Allergol Clin Immunol. 21; 242-244.
Fabris M, De Vita S, Visentini D, Fabro C, Picierno A, Lerussi A, Villalta D, Alessio MG, Tampoia MA, Tonutti E (2009) B-lymphocyte stimulator and a proliferation-inducting ligand serum levels in IgA-deficient patients with and without celiac disease. Ann NY Acad Sci. 1173; 268-273.
Borrelli M, Maglio M, Agnese M, Paparo F, Gentile S, Colicchio B, Tosco A, Auricchio R, Troncone R (2009) High density of intraepithelial TCR γ/δ lymphocytes and deposits of immunoglobulin (Ig)M anti tissue transglutaminase antibodies in the jejunum of celiac patients with IgA deficiency. Clin Exp Immunol. 160; 199-206.
Daniels JA, Lederman HM, Maitra A, Montgomery EA (2007) Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID). Am J Surg Pathol. 31; 1800-1812.
Agarwal S, Mayer L (2013) Diagnosis and treatment of gastrointestinal disorders in patients with primary immunodeficiency. Clin Gastroenterol Hepatol. 3; 1050-1063.
Kobrynski LJ, Mayer L (2011) Diagnosis and treatment of primary immunodeficiency disease in patients with gastrointestinal symptoms. Clin Immunol. 139; 238-248.
Blutt SE, Conner ME (2013) The gastrointestinal frontiers: IgA and viruses. Front Immunol.4; art. 402.
Makol A, Watt KD, Chowdhary VR (2011) Autoimmune hepatitis: a review of current diagnosis and treatment. Hepatitis Res Treat. Art. 390916; 1-11.
Mieli-Vergani G, Vergani D (2008) Autoimmune paediatric liver disease. World J Gastroenterol. 14; 3360-3367.
Bergbreiter A, Salzer U (2009) Common variable immunodeficiency: a multifaceted and puzzling disorder. Expert Rev Clin Immunol. 5; 167-180.
Verbruggen G, De Backer S, Deforce P, Demetter P, Cuvelier C, Veys E, Elewaut D (2005) X linked agammaglobulinemia and rheumatoid arthritis. Ann Rheum Dis. 64; 1075-1078.
Hernandez-Trujillo VP, Scalchunes C, Cunningham-Rundles Ch, Ochs HD, Bonilla FA, Paris K, Yel L, Sullivan KE (2014) Autoimmunity and inflammation in X-linked agammaglobulinemia. J Clin Immunol. 34; 627-632.
Blanco-Quiros A, Solis-Sanchez P, Garrote-Adrados JA, Arranz-Sanz E (2006) Common variable immunodeficiency. Old questions are getting clearer. Allergol Immunopathol. 34; 263-275.
Nimmerjahn F, Ravetch JV (2008) Anti-inflammatory actions of intravenous immunoglobulin. Ann Rev Immunol. 26; 513-533.
Nimmerjahn F, Ravetch JV (2010) Antibody-mediated modulation of immune responses. Immunological Rev. 236; 265-275.
Siedlar M, Strach M, Bukowska-Strakova K, Lenart M, Szaflarska A, Węglarczyk K, Rutkowska M, Baj-Krzyworzeka M, Pituch-Noworolska A, Kowalczyk D, Grodzicki T, Ziegler-Heitbrock L, Zembala M (2011) Preparations of intravenous immunoglobulins diminish the number and proinflammatory response of CD14+CD16+ monocytes in common variable immunodeficiency (CVID) patients. Clin Immunol. 139;122-132.
Bayry J, Fournier EM, Maddur MS, Vani J, Wootla B, Siberil S, Dimitrov JD, Lacroix-Desmazes S, Berdah M, Crabol Y, Oksenhendler E, Levy Y, Mouthon L, Sautes-Fridman C, Hermine O, Kaveri SV (2011) Intravenous immunoglobulins induces proliferation and immunoglobulin synthesis from patients with common immunodeficiency. J Autoimmun36: 9-15,
Rezaei N, Abolhassani H, Aghamogammadi A, Ochs HD (2011) Indications and safety of intravenous and subcutaneous immunoglobulin therapy. Expert Rev Clin Immunol. 7; 301-316.
Pituch-Noworolska A, Błaut-Szlósarczyk A, Zwonarz K (2010) Stosowanie preparatów immunoglobulin ludzkich – objawy niepożądane. In Polish. (The use of human immunoglobulins – adverse reactions). Polski Merkuriusz Lekarski. 29; 202-205.
Kobrynski L (2012) Subcutaneous immunoglobulin therapy. Biologics: Targ Ther. 6; 277-287.
Pituch-Noworolska A, Błaut-Szlósarczyk A (2010) Immunoglobulins: characteristics, indications for use and clinical effectiveness. Int Rev Allergol Clin Immunol. 16; 94-101.
Haddad E, Barnes D, Kafal A (2012) Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases. Transf Apheresis Sci. 46; 315-321.
Podjasek JC, Abraham RS (2012) Autoimmune cytopenias in common variable immunodeficiency. Front Immunol. 3: art. 189; 1-7.
Nijeboer P, van Wanrooij RLJ, Tack GJ, Mulder CJJ, Bouma G (2013) Update of the diagnosis and management of refractory celiac disease. Rev Gastroenterol Res Pract. Art. 518 483.
Al-Toma A, Verbeek WHM, Mulder CJJ (2007) The management of complicated celiac disease. Dig Dis. 25; 230-236.
Tennyson Ch, Green PHH (2011) The role of capsule endoscopy in patients with nonresponsive celiac disease. Gastrointest Endosc74; 1323-1324.
Sandhu BK, Fell JME, Beattie RM, Mitton SG, Wilson DC, Jenkins H (2010) Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. J Ped Gastroenterol Nutri. 50; S1-S13.
Burroughs L, Woolfrey A (2010) Hematopoietic cell transplantation for treatment of primary immune deficiencies. Cell Ther Transplant. doi:10.3205/ctt-2010-en-000077.01.
Cole TS, Johnstone IC, Pearce MS, Fulton B, Fulton B, Cant AJ, Gennery AR, Slatter MA (2012) Outcome of children requiring intensive care following haematopoietic SCT for primary immunodeficiency and other non-malignant disorders. BMT47; 40-45.
Gennery AR, Slatter MA, Grandin L, Taupin P, Cant AJ, Veys P, Amrolia PJ, Gaspar B, Davies EG, Friedrich W, Hoenig M, Notarangelo LD, Mazzolari E, Porta F, Bredius RGM, Lankester AC, Wulffraat NM, Seger R, Gungor T, Fasth A, Sedlacek P, Neven B, Blanche S, Fischer A, Cavazzana-Calvo, Landais P (2010) Transplantation of haematopoietic stem cells and long-term survival for primary immunodeficiencies. Eur J Allergy Clin Immunol. 126; 602-610.
Filipovich AH (2008) Hematopoietic cell transplantation for correction of primary immunodeficiencies. BMT42; S49-S52.
De la Morena MT (2013) Recent advances in transplantation for primary immune deficiency diseases. Clin Rev Allergy Immune. doi: 10.1007/s12016-013-8379-6.
Cha S-I, Fessler MB, Cool CD, Schwarz MI, Brown KK (2006) Lymphoid interstitial pneumonia: clinical features, associations and prognosis. Eur Respir J. 28; 364-369.
Matsubara M, Koizumi T, Wakamatsu T, Fujimoto K, Kubo K, Honda T (2008) Lymphoid interstitial pneumonia associated with common variable immunoglobulin deficiency. Inter Med. 47; 763-767.